SCHEMBL19609727

SCHEMBL19609727

O=C1c2ccccc2C(=O)N1C1C[C@H]1c1ccc(F)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMO Q99835 1/20 0.46
SLC6A2 P23975 3/20 0.43
SLC6A4 P31645 3/20 0.43
SLC6A3 Q01959 3/20 0.43
KMT2A Q03164 2/20 0.43
TSHR P16473 1/20 0.43
KDM1A O60341 2/20 0.42
HTR2A P28223 2/20 0.41
HTR2C P28335 2/20 0.41
HTR2B P41595 2/20 0.41
CYP19A1 P11511 1/20 0.40
MAOB P27338 1/20 0.40
MEN1 O00255 1/20 0.40
RPS6KA2 Q15349 1/20 0.40
CASP3 P42574 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22465825 1.00 SMO (0.46) SMOSLC6A2SLC6A4SLC6A3KMT2A
SCHEMBL19609318 1.00 SMO (0.46) SMOSLC6A2SLC6A4SLC6A3KMT2A
SCHEMBL30567560 1.00 SMO (0.46) SMOSLC6A2SLC6A4SLC6A3KMT2A
SCHEMBL30567561 1.00 SMO (0.46) SMOSLC6A2SLC6A4SLC6A3KMT2A
SCHEMBL16355425 1.00 SMO (0.46) SMOSLC6A2SLC6A4SLC6A3KMT2A
SCHEMBL19609316 1.00 SMO (0.46) SMOSLC6A2SLC6A4SLC6A3KMT2A
SCHEMBL15200670 1.00 SMO (0.46) SMOSLC6A2SLC6A4SLC6A3KMT2A
SCHEMBL15200669 1.00 SMO (0.46) SMOSLC6A2SLC6A4SLC6A3KMT2A
SCHEMBL1720311 0.86 SMO (0.56) SMOSLC6A2SLC6A3TSHRKDM1A
SCHEMBL1720667 0.86 SMO (0.56) SMOSLC6A2SLC6A3TSHRKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352322-B2 Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors Jubilant Epicore LLC (US) 2022-06-07 US disclosed
US-20200308110-A1 CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS Jubilant Epicore LLC 2020-10-01 US disclosed
WO-2017195216-A1 CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2017-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200308110-A1 CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS HDAC1, HDAC11, HDAC2 SMO 1802/4885SLC6A2 475/4885SLC6A4 532/4885
US-11352322-B2 Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors HDAC1, HDAC11, HDAC2 SMO 1802/4885SLC6A2 475/4885SLC6A4 532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.